← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Ganirelix

FDA approved · Rx

GnRH receptor antagonist

Also known as: Fyremadel, Ganirelix Acetate, Orgalutran, Ganirelixum, Antagon, Ganirelix (INN), CID 16134406

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 105 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Ganirelix is a synthetic peptide that blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. By blocking these receptors, it quickly lowers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which can prevent an early LH surge during fertility treatment.

What the evidence shows

Automatic summaryHuman trials

Ganirelix is FDA approved for inhibiting premature LH surges in women undergoing controlled ovarian hyperstimulation as part of fertility treatment. It is supported by over 100 registered human trials, including Phase 4 studies, and a substantial published literature, while uses outside this indication are not established.

Key facts

Molecular formula
C80H113ClN18O13
Molecular weight
1570.3 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

105registered studies
Phase 4most advanced phase
64completed (sample)
6recruiting (sample)

Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

Phase 4UnknownNCT00417183

Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

Phase 4CompletedNCT00417066

Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)

CompletedNCT00702273

Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development

Early Phase 1CompletedNCT01422395

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

210papers referencing Ganirelix

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.

Hum Reprod2000

Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.

J Clin Endocrinol Metab2002

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.

Hum Reprod2001

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.

Fertil Steril2001

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.